Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Stocks · News reference
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.